Acamprosate is the Most Promising Medication for Inhalant Abuse (Huffing) in Nursing Home Residents
Based on emerging evidence, acamprosate (666-999 mg twice daily) represents the most promising pharmacologic intervention for inhalant use disorder, particularly in patients with comorbid alcohol use disorder. 1
Rationale for Acamprosate
The mechanistic basis for using acamprosate in inhalant abuse is compelling:
- Shared neurochemical pathways: Inhalants, alcohol, and acamprosate all modulate glutamatergic and GABAergic neurotransmission 1
- Proven efficacy in alcohol dependence: Acamprosate demonstrates moderate-quality evidence for maintaining abstinence in alcohol use disorder (38% absolute probability of abstinence vs 25% with placebo) 2
- Case report success: A 39-year-old male with severe inhalant use disorder (16 cans of computer duster daily) achieved sustained abstinence with acamprosate 666 mg twice daily, later increased to 999 mg twice daily 1
Dosing Strategy
Start with acamprosate 666 mg twice daily, with option to increase to 999 mg twice daily if initial response is inadequate. This represents a lower starting dose than standard alcohol use disorder treatment, which is appropriate given the nursing home population's vulnerability to adverse effects.
Critical Context: No Established Pharmacotherapy Exists
A major caveat: There are no randomized controlled trials for any medication treating inhalant use disorder. 3 The Cochrane review found zero studies meeting inclusion criteria for inhalant dependence treatment, making this an evidence-free zone for traditional pharmacotherapy 3.
Why Not Other Medications?
- Disulfiram: Only addresses alcohol use, not inhalant cravings 1
- Antipsychotics: Only treat inhalant-induced psychotic symptoms (risperidone for hallucinations/delusions), not the underlying use disorder 4
- Benzodiazepines: Absolutely contraindicated in nursing home residents—midazolam shows 53% adverse event rate with 5.25-fold increased risk versus haloperidol 5. The American Geriatrics Society Beers Criteria recommends against benzodiazepines independent of diagnosis 5
Comprehensive Management Beyond Medication
Since pharmacotherapy evidence is minimal, the treatment foundation must include:
- Behavioral interventions: Cognitive behavioral therapy, motivational enhancement therapy, and relapse prevention strategies 4
- Environmental modifications: Remove access to inhalants, increase supervision
- Address comorbidities: Screen for depression, psychosis, and other substance use disorders 6
Special Considerations for Nursing Home Setting
In geriatric populations, start with the lowest effective dose due to altered pharmacokinetics and increased susceptibility to adverse events 5. Monitor for:
- Renal function (acamprosate is renally cleared)
- Multisystem toxicity from chronic inhalant exposure (cardiac, hepatic, neurologic, renal) 6
- Cognitive and behavioral deficits that may complicate treatment adherence 6
The combination of acamprosate for craving reduction plus intensive behavioral therapy represents the most evidence-informed approach currently available, though clinicians must recognize this is based on a single case report and mechanistic reasoning rather than robust clinical trial data.